Bringing a new medicine to market is one of the most complex, resource-intensive, and high-stakes undertakings in modern industry. The average drug development programme spans 10–15 years and costs — by the most widely cited industry estimates — somewhere between £1.5 billion and £2.3 billion from discovery to regulatory approval. Against that backdrop, the question of how pharmaceutical companies manage the operational, scientific, and regulatory demands of drug development is not an abstract one. It is a question with direct commercial consequences. And for a growing proportion of the global pharmaceutical industry, the answer involves a Contract Research Organisation — a CRO.
Understanding what a CRO is, what it actually does, and how it accelerates drug development is foundational knowledge for anyone working in pharmaceutical strategy, regulatory affairs, clinical operations, or life sciences investment. Here is a structured, data-informed answer to all three questions.
🔬 What Is a CRO?
A Contract Research Organisation (CRO) is a specialist service organisation that provides outsourced research, development, and regulatory support services to pharmaceutical, biotechnology, and medical device companies. CROs operate across the full drug development lifecycle — from preclinical research and clinical trial management through to regulatory submission support, post-market surveillance, and pharmacovigilance.
The CRO model emerged in the 1970s and 1980s as pharmaceutical companies began recognising that maintaining full in-house capability across every stage of drug development was neither operationally efficient nor commercially rational. The first CROs were relatively narrow in scope — focused primarily on clinical data management and biostatistics. Over the subsequent four decades, the CRO sector has evolved into a sophisticated, globally distributed industry with capabilities spanning virtually every technical and regulatory discipline in drug development.
The global CRO market was valued at approximately £62 billion in 2024 and is projected to reach £98 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 7.8%. This growth trajectory reflects not just the increasing volume of drug development activity globally, but a structural shift in how pharmaceutical companies organise their development operations — with outsourcing becoming the dominant model rather than the exception.
🏗️ What Does a CRO Actually Do?
The scope of CRO services is broad — and understanding it requires moving beyond the common but incomplete characterisation of CROs as simply “clinical trial managers.” A full-service CRO today operates across multiple distinct service domains:
Preclinical Research Services
Before a drug candidate enters human trials, it must demonstrate sufficient safety and pharmacological activity in preclinical studies. CROs provide in vitro and in vivo preclinical testing, toxicology studies, pharmacokinetic and pharmacodynamic profiling, and Good Laboratory Practice (GLP)-compliant safety studies. These preclinical packages form the scientific foundation for Investigational New Drug (IND) or Clinical Trial Authorisation (CTA) applications to regulatory authorities.
A 2024 industry analysis found that approximately 58% of pharmaceutical companies outsource at least a portion of their preclinical research to CROs — a figure that rises to 74% among small and mid-sized biotechnology companies that lack the laboratory infrastructure to conduct GLP-compliant studies in-house.
Clinical Trial Management
This is the domain most commonly associated with CROs — and for good reason. Clinical trial management is operationally complex, geographically distributed, and resource-intensive in ways that make full in-house execution impractical for most pharmaceutical companies.
CROs provide end-to-end clinical trial management services including:
- Protocol design and feasibility assessment — evaluating patient population availability, site capability, and regulatory pathway alignment across target markets
- Site identification and qualification — identifying and evaluating clinical trial sites against GCP compliance standards and patient recruitment potential
- Patient recruitment and retention — designing and executing recruitment strategies, with data-driven site performance monitoring
- Clinical data management — building and validating clinical databases, managing data entry and query resolution, and ensuring data integrity throughout the trial
- Biostatistics and statistical programming — designing statistical analysis plans, conducting pre-specified analyses, and generating the statistical outputs required for regulatory submissions
- Medical monitoring — providing ongoing medical oversight of trial safety data, adverse event assessment, and protocol deviation management
- Regulatory affairs support — preparing and submitting clinical trial applications, responding to regulatory authority queries, and supporting end-of-trial regulatory interactions
The scale of CRO involvement in global clinical trial activity is substantial. A 2024 IQVIA industry report estimated that CROs manage or co-manage approximately 65% of all industry-sponsored clinical trials globally — a figure that has increased from approximately 28% in 2000, reflecting the structural shift toward outsourced clinical operations over the past two decades.
Regulatory Affairs and Submission Support
Beyond clinical operations, CROs provide specialist regulatory affairs services — including dossier preparation in ICH CTD and ASEAN ACTD formats, regulatory strategy development, health authority meeting preparation, and submission management for markets across Europe, Asia-Pacific, and beyond.
For pharmaceutical companies entering complex multi-market regulatory environments — such as simultaneous submissions to the EMA, MHRA, Singapore’s HSA, Hong Kong’s PPB, and Malaysia’s NPRA — CRO regulatory affairs teams provide the market-specific expertise and submission infrastructure that would be prohibitively expensive to maintain in-house across all target markets simultaneously.
Pharmacovigilance and Post-Market Services
Post-approval regulatory obligations — including Periodic Safety Update Reports (PSURs), expedited adverse event reporting, signal detection, and risk management plan maintenance — represent a substantial and ongoing operational burden. CROs provide pharmacovigilance services that allow pharmaceutical companies to meet these obligations efficiently, with specialist PV systems and qualified persons for pharmacovigilance (QPPVs) available without the cost of building dedicated in-house infrastructure.
⚡ How Does a CRO Accelerate Drug Development?
The acceleration effect of CRO engagement operates through several distinct mechanisms — each of which addresses a specific constraint in the drug development timeline.
Access to Established Infrastructure and Expertise
Building the operational infrastructure required to run a Phase III clinical trial — validated clinical data management systems, GCP-trained monitoring staff, established site relationships, regulatory submission platforms — takes years and costs tens of millions of pounds. A CRO brings this infrastructure ready-built, allowing pharmaceutical companies to begin trial execution immediately rather than spending 12–24 months building operational capability before the first patient is enrolled.
This infrastructure advantage is particularly significant for small and mid-sized biotechnology companies — which represent an increasing proportion of the global drug development pipeline. A 2024 analysis of EMA new medicine approvals found that 43% of approved new medicines originated from companies with fewer than 500 employees — companies that, by definition, lack the internal scale to build full-service clinical development infrastructure.
Global Site Networks and Patient Recruitment Speed
Patient recruitment is consistently identified as the single greatest source of clinical trial delay — with industry data indicating that approximately 80% of clinical trials fail to meet their original recruitment timelines, and that recruitment delays account for an average of 6.6 months of additional trial duration per delayed study.
CROs address this constraint through established global site networks — with the largest full-service CROs maintaining relationships with thousands of clinical trial sites across dozens of countries, and proprietary patient recruitment databases and digital recruitment platforms that can be deployed immediately at trial initiation. The recruitment acceleration effect of CRO site networks is measurable: a 2023 industry benchmarking study found that CRO-managed trials achieved first patient enrolled an average of 4.2 months faster than sponsor-managed trials of equivalent complexity.
Parallel Workstream Execution
Drug development programmes involve multiple simultaneous workstreams — preclinical studies, manufacturing scale-up, regulatory strategy development, clinical protocol design, site qualification — that must be coordinated and executed in parallel to avoid sequential delays. CROs provide the project management infrastructure and specialist resource depth to run these workstreams simultaneously, compressing the overall development timeline in ways that sequential in-house execution cannot achieve.
Regulatory Expertise That Reduces Submission Failure Risk
Regulatory submission failures — dossiers rejected for inadequate data packages, incomplete module content, or format non-compliance — are among the most costly sources of drug development delay. A single Complete Response Letter (CRL) from a regulatory authority can add 12–18 months to a development programme and cost millions in remediation and resubmission expenses.
CROs with deep regulatory affairs expertise reduce this risk by ensuring that development programmes are designed from the outset to generate the data packages that regulatory authorities require — and that submission dossiers are prepared to the technical and formatting standards that maximise first-cycle approval probability.
📊 The CRO Sector in Asia-Pacific: A Growing Strategic Hub
The Asia-Pacific CRO market deserves specific attention — because it is growing faster than any other regional CRO market globally, and because it is increasingly central to global drug development strategy rather than a peripheral consideration.
The Asia-Pacific CRO market was valued at approximately £18.4 billion in 2024 and is projected to grow at a CAGR of 9.2% through 2030 — outpacing the global CRO market growth rate by more than a full percentage point. This growth is driven by several converging factors:
- Patient population scale and diversity — Asia-Pacific offers access to large, genetically diverse patient populations for clinical trials, including disease populations that are underrepresented in European and North American trial cohorts
- Regulatory modernisation — regulatory authorities across the region, including Singapore’s HSA, Hong Kong’s PPB, and Malaysia’s NPRA, have invested significantly in regulatory science capacity and international harmonisation — making Asia-Pacific submissions increasingly compatible with global regulatory strategies
- Cost efficiency — clinical trial operational costs in Asia-Pacific are typically 30–45% lower than equivalent trials conducted in Western Europe, without compromising GCP compliance standards
- Growing regional pharmaceutical industry — the expansion of domestic pharmaceutical and biotechnology industries across Asia-Pacific is generating substantial regional demand for CRO services independent of Western pharmaceutical company outsourcing
💡 Choosing the Right CRO: What the Data Suggests
Not all CROs are equivalent — and the choice of CRO partner is one of the most consequential decisions in a drug development programme. The data suggests several evidence-based selection criteria:
Therapeutic area expertise matters more than general operational scale. A 2024 industry survey found that therapeutic area alignment was the single most important factor in CRO selection for 67% of pharmaceutical company respondents — outranking price, geographic coverage, and company size.
Regulatory track record in target markets is a non-negotiable consideration for companies targeting multi-market submissions. A CRO with deep experience in EMA and MHRA submissions but limited Asia-Pacific regulatory expertise will not serve a company targeting simultaneous European and Asian market entry.
Technology infrastructure — particularly clinical data management systems, electronic data capture platforms, and regulatory submission portals — has become an increasingly important differentiator as regulatory authorities across Asia-Pacific and Europe move toward fully electronic submission requirements.
Size and scalability should be matched to programme needs. Large full-service CROs offer breadth and global reach; specialist niche CROs offer deeper therapeutic or regulatory expertise in specific domains. Many sophisticated pharmaceutical companies use a hybrid CRO model — engaging a full-service CRO for clinical operations while retaining specialist niche CROs for specific regulatory markets or technical disciplines.
The Strategic Reality
A CRO is not simply a cost-reduction tool or a staffing solution for pharmaceutical companies that lack internal headcount. At its most strategically valuable, a CRO is a development acceleration partner — bringing infrastructure, expertise, site networks, regulatory intelligence, and operational capacity that compress timelines, reduce submission failure risk, and allow pharmaceutical companies to focus their internal resources on the scientific and commercial decisions that only they can make.
In a drug development environment where time to market is directly correlated with commercial value — where a six-month acceleration in approval timeline can represent hundreds of millions in additional revenue — the strategic case for CRO engagement is not just operationally compelling. It is commercially fundamental.
